Sono-Photodynamic Therapy (SPDT)
Unfortunately, there are no randomized, placebo-controlled trials which evaluate the effectiveness of SPDT. However, studies have shown that SPDT promotes apoptosis (programmed cell death) in cancer cells, while also acting to propose metastasis.
Sono-photodynamic Therapy in Use
The SPDT procedure entails first administering a sensitizing agent, which is uniquely taken up by cancer cells but not healthy cells. This sensitizing agent makes cancer cells susceptible to specific frequencies of therapeutic ultrasound and precise wavelengths of light. It is very important to use the proper sensitizing agent, as well as the correct type of ultrasound and light applications.
The sensitizing agent remains inside cancer cells for a period of 1-2 weeks. During this time, SPDT is administered to take advantage of the susceptible cancer cells. We have found SPDT to be a safe, well-tolerated procedure which complements other integrative therapies very well.